<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Micafungin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01141</strong>&#160; (APRD01114)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01141/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01141/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01141.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01141.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01141.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01141.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01141.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01141">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Mycamine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antifungal-agents">Antifungal Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>235114-32-6</td></tr><tr><th>Weight</th><td>Average: 1270.274<br>Monoisotopic: 1269.438350313</td></tr><tr><th>Chemical Formula</th><td>C<sub>56</sub>H<sub>71</sub>N<sub>9</sub>O<sub>23</sub>S</td></tr><tr><th>InChI Key</th><td>PIEUQSKUWLMALL-YABMTYFHSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">{5-[(1S,2S)-2-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-3-[(1R)-2-carbamoyl-1-hydroxyethyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[(4-{5-[4-(pentyloxy)phenyl]-1,2-oxazol-3-yl}benzene)amido]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^{9,13}]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl}oxidanesulfonic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCCCCOC1=CC=C(C=C1)C1=CC(=NO1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC(OS(O)(=O)=O)=C(O)C=C1)[C@H](O)CC(N)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids and Derivatives</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Cyclic Peptides</td></tr><tr><th>Alternative parents</th><td>Macrolactams; N-acyl-alpha Amino Acids and Derivatives; Tyrosols and Derivatives; Phenylsulfates; Benzamides; Phenol Ethers; Benzoyl Derivatives; Alkyl Aryl Ethers; Sulfuric Acid Monoesters; Tertiary Carboxylic Acid Amides; Pyrrolidines; Isoxazoles; Tertiary Amines; Secondary Alcohols; Primary Carboxylic Acid Amides; Secondary Carboxylic Acid Amides; 1,2-Diols; Enolates; Polyamines; Enols; Carboxylic Acids</td></tr><tr><th>Substituents</th><td>n-acyl-alpha amino acid or derivative; macrolactam; tyrosol derivative; phenylsulfate; benzamide; benzoyl; phenol ether; sulfuric acid monoester; phenol derivative; alkyl aryl ether; benzene; sulfate-ester; isoxazole; tertiary carboxylic acid amide; sulfuric acid derivative; azole; pyrrolidine; secondary alcohol; secondary carboxylic acid amide; 1,2-diol; carboxamide group; polyol; tertiary amine; primary carboxylic acid amide; enolate; carboxylic acid; ether; enol; polyamine; alcohol; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use in the treatment of candidemia, acute disseminated candidiasis, and certain other invasive <i>Candida</i> infections, as well as esophageal candidiasis, and prophylaxis of <i>Candida</i> infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.</td></tr><tr><th>Pharmacodynamics</th><td>Formerly known as FK463, micafungin is a semisynthetic lipopeptide synthesized from a fermentation product of <i>Coleophoma empetri</i> that works as an antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis. Depending on its concentration, micafungin may be fungicidal against some <i>Candida</i>, but is usually fungistatic against <i>Apergillus</i>. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.</td></tr><tr><th>Mechanism of action</th><td>Micafungin inhibits the synthesis of beta-1,3-D-glucan, an essential component of fungal cell walls which is not present in mammalian cells. It does this by inhibiting beta-1,3-D-glucan synthase.</td></tr><tr><th>Absorption</th><td>Not absorbed orally</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>0.39 &#177; 0.11 L/kg [adult patients with esophageal candidiasis]</li>
</ul></td></tr><tr><th>Protein binding</th><td>Highly (&gt;99%) protein bound in vitro, independent of plasma concentrations over the range of 10 to 100 &#181;g/mL. The primary binding protein is albumin; however, micafungin, at therapeutically relevant concentrations, does not competitively displace bilirubin binding to albumin. Micafungin also binds to a lesser extent to a<sub>1</sub>-acid-glycoprotein.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Micafungin is metabolized to M-1 (catechol form) by arylsulfatase, with further metabolism to M-2 (methoxy form) by catechol-O-methyltransferase. M-5 is formed by hydroxylation at the side chain (w-1 position) of micafungin catalyzed by cytochrome P450 (CYP) isozymes. Even though micafungin is a substrate for and a weak inhibitor of CYP3A in vitro, hydroxylation by CYP3A is not a major pathway for micafungin metabolism in vivo.</p></td></tr><tr><th>Route of elimination</th><td>Fecal excretion is the major route of elimination (total radioactivity at 28 days was 71% of the administered dose).</td></tr><tr><th>Half life</th><td>14-17 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>0.359 +/- 0.179 mL/min/kg [Adult Patients with IC with 100 mg]</li>
	<li>0.321 +/- 0.098 mL/min/kg [<span class="caps">HIV</span>- Positive Patients with EC with 50 mg]</li>
	<li>0.327 +/- 0.093 mL/min/kg [<span class="caps">HIV</span>- Positive Patients with EC with 100 mg]</li>
	<li>0.340 +/- 0.092 mL/min/kg [<span class="caps">HIV</span>- Positive Patients with EC with 150 mg]</li>
	<li>0.214 +/- 0.031 mL/min/kg [hematopoietic stem cell transplant recipients 3 mg/kg]</li>
	<li>0.204 +/- 0.036 mL/min/kg [hematopoietic stem cell transplant recipients 4 mg/kg]</li>
	<li>0.224 +/- 0.064 mL/min/kg [hematopoietic stem cell transplant recipients 6 mg/kg]</li>
	<li>0.223 +/- 0.081 mL/min/kg [hematopoietic stem cell transplant recipients 8 mg/kg]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Intravenous LD<sub>50</sub> in rats is 125mg/kg. In dogs it is &gt;200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.</td></tr><tr><th>Affected organisms</th><td><ul><li>Aspergillis, Candida and other fungi</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.8383</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.8524</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6464</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7906</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6752</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9279</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9428</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8485</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7911</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5853</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7414</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7017</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8251</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.693</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.5393</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7703</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.563
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Carcinogens  
        </td>
        <td>
            0.5763
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9916
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5651 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9686
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.716
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Astellas pharma us inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.astellas.com">Astellas Pharma Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, powder, lyophilized, for solution</td><td>Intravenous drip</td><td>100 mg</td></tr><tr><td>Injection, powder, lyophilized, for solution</td><td>Intravenous drip</td><td>50 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>